The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.
Last month, Arexvy received approval from the US Food and Drug Administration (FDA) for the same indication.
Arexvy contains a combination of recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3) and GSK’s AS01E adjuvant.
The EC approval follows a positive opinion from the European Medicines Agency’s committee on medicinal products for human use (CHMP) in April 2023.
GSK chief scientific officer Tony Wood stated: “Thousands of older adults across Europe suffer serious respiratory illness due to RSV each year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation.
“Our strong manufacturing capability and scale, including from our vaccine manufacturing site in Belgium, means we are ready to deliver the vaccine as countries begin to launch.”
The marketing authorisation from the EC was supported by data obtained from a pivotal Phase III AReSVi-006 (adult respiratory syncytial virus) trial.
Arexvy demonstrated a statistically significant and clinically meaningful 82.6% overall efficacy against RSV-LRTD in adult patients.
Its efficacy in older adults with one or more underlying medical conditions such as certain cardiorespiratory and endocrine-metabolic disorders was 94.6%.
The vaccine will be available before the 2023/2024 RSV season, which begins later this year.